News Releases

News Releases

Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

May 09, 2023
- Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 - SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc.  (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.

Apr 16, 2023
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology RAHWAY, N.J.

Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 09, 2023
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases,

Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress

Feb 28, 2023
– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies – –  Prometheus intends to advance PRA023 into Phase 3 studies for UC and CD in 2023 –   – Initiated a third Phase 2 of PRA023 into SSc-ILD, demonstrating pipeline-in-a-product candidate

Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)

Feb 22, 2023
- Digital Oral Presentation on APOLLO-CD Phase 2a primary and secondary results to be presented on March 3 r d - - Oral Presentation on ARTEMIS-UC Phase 2 primary and secondary endpoint data from Cohort 1 to be presented on March 4 th - SAN DIEGO, Feb.

Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference

Feb 09, 2023
SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today

Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 03, 2023
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc.  (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment

Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock

Dec 08, 2022
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of

Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock

Dec 07, 2022
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of

Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb

Dec 07, 2022
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p
Displaying 1 - 10 of 53